Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (6): 1644-1649.doi: 10.13481/j.1671-587X.20220634
• Review • Previous Articles Next Articles
-
Received:2022-02-10Online:2022-11-28Published:2022-12-07
CLC Number:
- R574
Cite this article
share this article
| 1 | ZHANG N N， ZHANG H， JIANG L Q， et al. A novel method of sacral nerve stimulation for colonic inflammation［J］.Neurogastroenterol Motil，2020，32（6）： e13825. |
| 2 | ANSALDO E， FARLEY T K， BELKAID Y. Control of immunity by the microbiota［J］. Annu Rev Immunol， 2021， 39： 449-479. |
| 3 | HERNÁNDEZ M， CANFORA E E， JOCKEN J W E， et al. The short-chain fatty acid acetate in body weight control and insulin sensitivity［J］.Nutrients，2019，11（8）： 1943. |
| 4 | DUDIK B， SEPOVA H K， BILKOVA A. Inflammatory bowel disease： factors involved in pathogenesis［J］. Ceska Slov Farm，2018，67（3）：95-100. |
| 5 | KUSHKEVYCH I， DORDEVIĆ D， KOLLAR P，et al. Hydrogen sulfide as a toxic product in the small-large intestine axis and its role in IBD development［J］. J Clin Med， 2019， 8（7）： 1054. |
| 6 | GEVERS D， KUGATHASAN S， KNIGHTS D，et al. A microbiome foundation for the study of Crohn’s disease［J］. Cell Host Microbe， 2017， 21（3）： 301-304. |
| 7 | BELKAID Y， HAND T W. Role of the microbiota in immunity and inflammation［J］. Cell， 2014， 157（1）： 121-141. |
| 8 | GONZÁLEZ OLMO B M， BUTLER M J， BARRIENTOS R M. Evolution of the human diet and its impact on gut microbiota， immune responses， and brain health［J］. Nutrients， 2021， 13（1）： 196. |
| 9 | MORGAN X C， TICKLE T L， SOKOL H， et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment［J］. Genome Biol， 2012， 13（9）： R79. |
| 10 | MOTTAWEA W， CHIANG C K， MÜHLBAUER M， et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease［J］. Nat Commun， 2016， 7： 13419. |
| 11 | GRACIE D J， HAMLIN P J， FORD A C. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment［J］. Lancet Gastroenterol Hepatol， 2019， 4（8）： 632-642. |
| 12 | SINGH V， KUMAR M， BSAN YEOH， et al. Inhibition of interleukin-10 signaling induces microbiota-dependent chronic colitis in apolipoprotein E deficient mice［J］. Inflamm Bowel Dis， 2016， 22（4）： 841-852. |
| 13 | FRANZOSA E A， SIROTA-MADI A， AVILA-PACHECO J， et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease［J］. Nat Microbiol， 2019， 4（2）： 293-305. |
| 14 | KIM M J， KIM E， KANG B， et al.Anti-Saccharomyces cerevisiae antibody in pediatric Crohn’s disease patients without mucosal healing is a useful marker of mucosal damage［J］. Gut Liver， 2021， 15（5）： 763-770. |
| 15 | GUGGINO G， MAURO D， RIZZO A， et al. Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis［J］. Arthritis Rheumatol， 2021， 73（7）： 1189-1199. |
| 16 | MUKHOPADHYA I， HANSEN R， MEHARG C，et al.The fungal microbiota of de-novo paediatric inflammatory bowel disease［J］. Microbes Infect， 2015， 17（4）： 304-310. |
| 17 | LIGUORI G， LAMAS B， RICHARD M L， et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients［J］. J Crohns Colitis， 2016， 10（3）： 296-305. |
| 18 | SASSON A N， INGRAM R J M， ZHANG Z X， et al. The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease［J］. Lancet Gastroenterol Hepatol， 2021， 6（9）： 754-769. |
| 19 | JAIN U， MVER HEUL A， XIONG S S， et al. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice［J］. Science， 2021， 371（6534）： 1154-1159. |
| 20 | DORON I， MESKO M， LI X V， et al. Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn’s disease［J］. Nat Microbiol， 2021， 6（12）： 1493-1504. |
| 21 | TRUNK K， PELTIER J， LIU Y C， et al. The type Ⅵsecretion system deploys antifungal effectors against microbial competitors［J］. Nat Microbiol， 2018， 3（8）： 920-931. |
| 22 | FILYK H A， OSBORNE L C. The multibiome： the intestinal ecosystem’s influence on immune homeostasis，health， and disease［J］. EBioMedicine， 2016， 13： 46-54. |
| 23 | LAMAS B， RICHARD M L， LEDUCQ V， et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands［J］. Nat Med， 2016， 22（6）： 598-605. |
| 24 | COSNES J， GOWER-ROUSSEAU C， SEKSIK P，et al.Epidemiology and natural history of inflammatory bowel diseases［J］. Gastroenterology， 2011，140（6）：1785-1794. |
| 25 | XU J Y， YU P C， WU L J， et al. Effect of Trichinella spiralis intervention on TNBS-induced experimental colitis in mice［J］.Immunobiology， 2019，224（1）： 147-153. |
| 26 | PANELLI S， EPIS S， COCOCCIONI L， et al. Inflammatory bowel diseases， the hygiene hypothesis and the other side of the microbiota： parasites and fungi［J］. Pharmacol Res， 2020， 159： 104962. |
| 27 | VARELA E， MANICHANH C， GALLART M， et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis［J］. Aliment Pharmacol Ther， 2013， 38（2）： 151-161. |
| 28 | SOKOL H， PIGNEUR B， WATTERLOT L， et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients［J］. Proc Natl Acad Sci U S A， 2008， 105（43）： 16731-16736. |
| 29 | YUAN H D， MA Q Q， CUI H Y， et al. How can synergism of traditional medicines benefit from network pharmacology？ ［J］. Molecules， 2017， 22（7）： 1135. |
| 30 | REYES A， HAYNES M， HANSON N， et al. Viruses in the faecal microbiota of monozygotic twins and their mothers［J］. Nature， 2010， 466（7304）： 334-338. |
| 31 | KHARDORI N， STEVAUX C， RIPLEY K. Antibiotics： from the beginning to the future： part 2［J］. Indian J Pediatr， 2020， 87（1）： 43-47. |
| 32 | NORMAN J M， HANDLEY S A， BALDRIDGE M T， et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease［J］.Cell， 2015，160（3）：447-460. |
| 33 | CLOONEY A G， SUTTON T D S， SHKOPOROV A N， et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease［J］. Cell Host Microbe， 2019， 26（6）： 764-778.e5. |
| 34 | SHKOPOROV A N， CLOONEY A G， SUTTON T D S， et al. The human gut virome is highly diverse， stable， and individual specific［J］. Cell Host Microbe， 2019， 26（4）： 527-541.e5. |
| 35 | DUAN Y， YOUNG R， SCHNABL B. Bacteriophages and their potential for treatment of gastrointestinal diseases［J］.Nat Rev Gastroenterol Hepatol，2022，19（2）： 135-144. |
| 36 | ANDREWS C N， GRIFFITHS T A， KAUFMAN J， et al. Mesalazine （5-aminosalicylic acid） alters faecal bacterial profiles， but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome［J］. Aliment Pharmacol Ther， 2011， 34（3）： 374-383. |
| 37 | NISHIDA A， INOUE R， INATOMI O， et al. Gut microbiota in the pathogenesis of inflammatory bowel disease［J］. Clin J Gastroenterol， 2018， 11（1）： 1-10. |
| 38 | PITCHER M C， BEATTY E R， CUMMINGS J H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis［J］. Gut， 2000， 46（1）： 64-72. |
| 39 | BUSQUETS D， MAS-DE-XAXARS T， LÓPEZ-SILES M，et al. Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn’s disease［J］.J Crohns Colitis，2015，9（10）： 899-906. |
| 40 | FLORIN T H J， WRIGHT J D， JAMBHRUNKAR S D，et al. A well-tolerated and rapidly acting thiopurine for IBD？ ［J］. Drug Discov Today， 2019， 24（1）： 37-41. |
| 41 | HUANG E Y， INOUE T， LEONE V A， et al. Using corticosteroids to reshape the gut microbiome： implications for inflammatory bowel diseases［J］. Inflamm Bowel Dis， 2015， 21（5）： 963-972. |
| 42 | SIPPOLA S， HAIJANEN J， GRÖNROOS J， et al. Effect of oral moxifloxacin vs intravenous ertapenem plus oral levofloxacin for treatment of uncomplicated acute appendicitis： the APPAC II randomized clinical trial［J］. JAMA， 2021， 325（4）： 353-362. |
| 43 | ABENAVOLI L， SCARPELLINI E， COLICA C，et al. Gut microbiota and obesity： a role for probiotics［J］. Nutrients， 2019， 11（11）： 2690. |
| 44 | BUTTERWORTH A D， THOMAS A G， AKOBENG A K. Probiotics for induction of remission in Crohn’s disease［J］. Cochrane Database Syst Rev， 2008， 2008（3）： CD006634. |
| 45 | RACHUL C， MARCON A R， COLLINS B， et al. COVID-19 and ‘immune boosting’ on the Internet： a content analysis of Google search results［J］. BMJ Open， 2020， 10（10）： e040989. |
| 46 | QURAISHI M N， WIDLAK M， BHALA N， et al. Systematic review with meta-analysis： the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection［J］. Aliment Pharmacol Ther， 2017， 46（5）： 479-493. |
| 47 | ANDERSON J L， EDNEY R J， WHELAN K. Systematic review： faecal microbiota transplantation in the management of inflammatory bowel disease［J］. Aliment Pharmacol Ther， 2012， 36（6）： 503-516. |
| 48 | SHA S， LIANG J， CHEN M， et al. Systematic review： faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children［J］. Aliment Pharmacol Ther， 2014， 39（10）： 1003-1032. |
| 49 | WEINGARDEN A R， VAUGHN B P. Intestinal microbiota， fecal microbiota transplantation， and inflammatory bowel disease［J］. Gut Microbes， 2017， 8（3）： 238-252. |
| 50 | 李姗姗， 杨长青. 门静脉高压性肠病——一种不该忽视的门静脉高压并发症［J］.临床肝胆病杂志，2022，38（6）：1237-1241. |
| [1] | Xiong LIN,Linghang QU,Jing XU,Chunlian LIU,Shuiqing LI,Yanju LIU. Improvement effects of Atractylodes rhizome oil and Atractylodes rhizome ethanol extract on ulcerative colitis model mice and comparison of their curative effects [J]. Journal of Jilin University(Medicine Edition), 2022, 48(5): 1247-1255. |
| [2] | Qi LIU,Xin XU,Zhenggen WANG. Effect of calycosin on intestinal mucosal barrier function in cirrhosis rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 391-398. |
| [3] | . Research progress in application of electronic nose in diagnosis of intestinal disease [J]. Journal of Jilin University(Medicine Edition), 2020, 46(6): 1332-1337. |
| [4] | LI Jia, YANG Luoluo, ZHOU Changli, HE Ping, SUN Xun, MENG Xiangwei. Analysis on risk factors related to incidence of patientswithcolorectal polyps [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 646-650. |
| [5] | . Research progress in role of IL-10 cytokine family in intestinal fibrosis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 849-851. |
| [6] | LIU Yang, LIU Zhi, LI Fenge, KONG Fanli. Therapeutic effect of mosapride citrate on gastrointestinal tract function disorder of patients with Parkinson's syndrome [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 125-129. |
| [7] | LI Hui,ZHAO Li-jing,DU Yu,YANG Tie-zheng,LI Guo-feng,CHEN Liang,ZHI Chen-yang,LI Na,ZHOU Jian-hua. Therapeutic effect of suppository of Jiechang An combined with Shuxue Ning on rats with ulcerative colitis and their mechanisms [J]. Journal of Jilin University Medicine Edition, 2013, 39(3): 488-493. |
| [8] | WANG Min, JI Fu-jian, JIN Hong-yong,CHEN Xue-bo, YU Jie, FANG Xue-dong. Analysis of clinico-pathologic features on |metastasis of |lymph nodes around rectum in patients with rectal carcinoma [J]. J4, 2011, 37(2): 345-350. |
| [9] | WANG Zhe, JIANG Yi-Zhong, SONG Yang, ZHOU Chang-Yu. Changes of clotting function indexes in elder patients with ulcerative colitis and significances [J]. J4, 2009, 35(3): 553-555. |
| [10] | CHEN Xi，YANG Shi-zhong，CHI Bao-rong. Reproduction of rat inflammatory bowel disease model and intervention effect of Changkangyin on it [J]. J4, 2008, 34(2): 262-265. |
| [11] | YU Jin-hai,SOU Jian,LI You-zhu,WANG Zhong-yi,LIU Guo-hui,WANG Quan. Inhibitory effect of Fe3+-CMC on expressions of TGF-β and FGF [J]. J4, 2007, 33(6): 1026-1028. |
| [12] | . Clinical application of nutrision in intestinal preparing before colonoscopy [J]. J4, 2005, 31(1): 142-143. |
| [13] | . Clinical significances of mean platelet volume and D-dipolymerin patients with inflammatory bowel disease [J]. J4, 2004, 30(6): 947-948. |
| [14] | . Clinical curative effects of ChangYanKang oral liquid for ulcerative colitis [J]. J4, 2004, 30(5): 785-786. |
| [15] | LI Tiantian, YANG Lanlan, JIA Shengnan, JIN Zhenjing. A case report of diagnosis and treatment of abdominal cocoon and literature review [J]. Journal of Jilin University Medicine Edition, 2015, 41(01): 172-174. |
